Reports of 17 Chinese patients with tumor-induced osteomalacia

J Bone Miner Metab. 2017 May;35(3):298-307. doi: 10.1007/s00774-016-0756-9. Epub 2016 Apr 16.

Abstract

Tumor-induced osteomalacia (TIO) is a rare acquired form of hypophosphatemic osteomalacia, which is usually attributed to the overproduction of fibroblast growth factor 23 (FGF-23) by benign mesenchymal neoplasms. Localization and thereafter surgical resection of tumors lead to a cure. The present study aimed to investigate the clinical data, diagnostic methods, and follow-up after tumor resection at one medical center in Shanghai to characterize the profile of this rare disorder and to share our successful experience in diagnosis and treatment. Twenty-three patients with adult-onset hypophosphatemia osteomalacia seen in Shanghai Sixth People's Hospital from 2009 to 2014 and 95 normal individuals were enrolled. After taking a medical history and performing a physical examination, we analyzed the laboratory results (including the serum FGF-23 levels) and localized the tumors by 18F-fluorodeoxyglucose positron emission tomography and computed tomography (18F-FDG PET/CT), 99mTc-octreotide (99mTc-OCT) scintigraphy, and magnetic resonance imaging (MRI). On the basis of the results of laboratory tests and imaging findings, tumor resection was conducted in 17 patients with a certain diagnosis of TIO. The results demonstrated that the 17 patients (nine men and eight women, average age 46.6 ± 12.9 years) had TIO. FGF-23 level was elevated in 94.1 % of patients (16 of 17 patients) . Serum phosphorus level decreased in 100 % of patients. 18F-FDG PET/CT revealed five tumors, 99mTc-OCT scintigraphy revealed two tumors, physical examination revealed nine tumors, and MRI revealed one tumor, among which 58.8 % of the causative tumors (10 of 17 tumors) were located in the lower extremities. After tumor resection, serum phosphorus levels normalized in 100 % of patients (all 17 patients) in 4-21 days and FGF-23 levels decreased in 90 % of patients (nine of ten patients). We found 64.7 % of the tumors (11 of 17 tumors) were phosphaturic mesenchymal tumors or a phosphaturic mesenchymal tumor mixed connective tissue variant. Measurement of serum phosphorus and FGF-23 levels in patients with suspected TIO is of paramount importance for diagnosing of TIO. 18F-FDG PET/CT, 99mTc-OCT scintigraphy, and physical examination play a considerable role in revealing TIO-associated tumors. TIO-associated tumors were more frequently located in the lower extremities than in other places; thus, the lower extremities need to be carefully checked. Complete surgical resection results in normalization of parameters in laboratory tests and relief of symptoms of TIO patients.

Keywords: 18F-Fluorodeoxyglucose positron emission tomography and computed tomography; Fibroblast growth factor 23; Tumor-induced osteomalacia.

MeSH terms

  • Adult
  • Aged
  • Alkaline Phosphatase / blood
  • Asian People / genetics*
  • China
  • Female
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / blood
  • Follow-Up Studies
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neoplasms, Connective Tissue / blood
  • Neoplasms, Connective Tissue / diagnostic imaging
  • Neoplasms, Connective Tissue / pathology*
  • Neoplasms, Connective Tissue / surgery
  • Octreotide / analogs & derivatives
  • Octreotide / chemistry
  • Organotechnetium Compounds / chemistry
  • Osteomalacia
  • Paraneoplastic Syndromes
  • Phosphorus / blood
  • Positron Emission Tomography Computed Tomography
  • Young Adult

Substances

  • 99mTc-octreotide
  • FGF23 protein, human
  • Organotechnetium Compounds
  • Phosphorus
  • Fibroblast Growth Factors
  • Fibroblast Growth Factor-23
  • Alkaline Phosphatase
  • Octreotide

Supplementary concepts

  • Oncogenic osteomalacia